In patients with asthma receiving long-term glucocorticoid treatment, does etidronate, calcium, or both reduce fracture rates?
Outcomes: New vertebral and nonvertebral fractures. Patient follow-up: 99% (intention-to-treat analysis).
M a i n r e s u l t s
The groups did not differ for mortality (10%, 24%, 16%, and 16% in the etidronate-only, calcium-only, etidronate-plus-calcium, and no-treatment groups, respectively); symptomatic fractures (6%, 8%, 10%, and 7%, respectively); or symptomatic fractures, semiquantitative vertebral fractures, or both (16% 18%, 16%, and 20%, respectively). Groups receiving etidronate compared with groups not receiving etidronate, and groups receiving calcium compared with groups not receiving calcium, did not differ for rates of any fractures, respectively (Table) .
C o n c l u s i o n
In patients with asthma receiving long-term glucocorticoid treatment, etidronate and calcium used alone or combined did not reduce fracture rates. 
C o m m e n t a r y
Campbell and colleagues studied the effects of etidronate (with and without calcium), calcium, or placebo on bone mineral density (BMD) and fractures in patients taking oral or inhaled glucocorticoids or both for asthma. Patients randomized to etidronate had a 5% increase in lumbar spine BMD. No difference between groups existed in hip BMD or fractures. Calcium, 500 mg/d, did not have any additional benefit. How does one interpret these results? Lack of statistical power may explain the negative findings because the study achieved only 50% of its recruitment target. Previous studies show that etidronate is effective at preventing bone loss in patients treated with glucocorticoids, and 1 trial of shorter duration showed a reduction in height loss and vertebral fracture (1) . Perhaps the effect of etidronate was diminished because patients had other risk factors for fractures that were not assessed or treated, although levels of exercise did not differ between treatment groups. Alternatively, etidronate may not be potent enough for longterm fracture prevention. The lack of an additional effect of calcium is not surprising; the dose was low, and the data for calcium and vitamin D in glucocorticoid-induced osteoporosis are not compelling (1) .
How can we apply findings from this study to the management of glucocorticoid-induced osteoporosis? Until further long-term studies of the newer bisphosphonates are completed, patients with low-trauma fractures should be prescribed a bisphosphonate, risedronate or alendronate, regardless of BMD (1). Men and women taking oral or inhaled steroids at doses ≥ 1000 µg/d should have BMD testing. For patients with T scores < −2.0 to −1.5, prescription of bisphosphonates should be considered.
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